|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
Clinical TrialsGlens Falls Hospital
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Prevention Trials:
| |
| |
| |
| |
|
C
40101 Cyclophosphamide &
Doxorubicin (4 vs. 6 cycles) vs. Paclitaxel (12 weeks vs. 18 weeks) as
adjuvant therapy for women with node negative breast cancer.
N B36
A clinical trial of adjuvant therapy comparing six
cycles of 5FU, Epirubicin, and Cyclophosphamide (FEC) to 4 cycles of
Adriamycin and Cyclophosphamide (AC) in patients with node-negative
breast cancer.
N B37 A randomized trial of adjuvant chemotherapy for radically resected loco-regional relapse of breast cancer.
N B38 A phase III, adjuvant trial comparing three chemo regimens in women with node-positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); dose-dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC>P); DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC>PG).
N B39 A randomized phase III study of conventional whole breast irradiation (WBI) vs. partial breast irradiation (PBI) for women with stage O, I or II breast cancer.
N B40 A randomized phase III trial of Neoadjuvant Therapy in Patients with Palpable & Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when administered before AC with or without Bevacizumab and Correlative Science Studies attempting to identify predictors of high likelihood for pCR with each of the regimens.
N B42 Trial to determine the efficacy of 5 years of Letrozole compared to placebo in patients completing 5 years of hormonal therapy of an aromatase inhibitor (AI) or Tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor positive breast cancer.
CTSU S-0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
CTSU PACCT-1 Program for the Assessment of Clinical Cancer Tests (PACCT-1); Trial Assigning Individualized Options for Treatment; The TAILORx Trial.
CTSU SO500 A randomized phase III trial to test the strategy of changing therapy vs. maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell levels at first follow-up assessment.
V V0501 A Phase II trial of Arimidex added sequentially to Zoladex in premenopausal women with metastatic breast cancer.
V V0512 QOL Companion Study for V0512.
P Lapatinib: EGF 103659 Expanded Access Protocol of Lapatinib and Capecitabine therapy in ErbB2 Over-Expressing locally advanced or metastatic breast cancer.
C 80405 A Phase III Trail of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the combination of Bevacizumab and Cetuximab for patients with Untreated Metastatic Adenocarcinoma of the colon or rectum.
CTSU-E5204 Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation.
N C10 A Phase II Trial of 5-Fluorouracil, Leucovorin & Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumbab for Patients with Unresectable Stage IV Colon Cancer & a Synchronous Asymptomatic Primary Tumor.
N
R-04
A trial comparing pre-op RT and
Capecitabine with pre-op RT and continuous IV infusion (CV) of 5FU in
the treatment of patients with operable rectal cancer.
C 80101 Phase III intergroup trial of adjuvant chemo/RT after resection of gastric or gastroesphageal adenocarcinoma.
C 80302 A Phase II trial of preoperative irinotecan, cisplatin and radiation in esophageal cancer.
CTSU-Z9001 Phase III randomized double-blind study of Gleevec (STI571) vs. placebo in patients following the resection of primary GIST.
CTSU E-1302 A Randomized Phase III, placebo-controlled trial of docetaxel vs. docetaxel plus ZD1839 (Iressa, gefitinib) in performance status 2 or previously treated patients with recurrent or metastatic head & neck cancer.
P PNH Explore: Examine PNH by level of CD59 on red and white blood cells, in bone marrow failure syndromes.
C 10303 Phase IIB study of molecular responses to Imatinib at standard or increased doses for previously untreated patients with CML in chronic phase.
SCLC Limited
SCLC
Extensive
SCLC Relapsed
NSCLC Stage III
NSCLC Advanced
P Pfizer A Randomized Phase 2 Trial of Paclitaxel, Carboplatin and Bevacizumab With or Without PF-3512676 As First Line Treatment of Patients With Advanced NonSquamous Non-Small Cell Lung Cancer
C 50202 Intensive Chemotherapy and Immunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma.
C 50303 Phase III randomized study of R-CHOP vs. dose-adjusted EPOCH-R with molecular profiling in untreated DeNova diffuse large B-cell lymphomas.
C 50401 A Randomized Phase II Trial of Rituximab vs. Lenalidomide (RevlimidTM, CC-5013)(IND#73034) vs. Rituximab + Lenalidomide in Recurrent Folicular Non-Hodgkin Lymphoma (NHL) After Relapse from a Rituximab-Containing Combination Regimen.
C
59905 Randomized
phase III trial of ABVD vs. Stanford V +/- RT in locally extensive and
advanced stage Hodgkin’s disease with 0-2 risk factors.
C
10105 Phase
II study of an oral VEGF receptor tyrosine kinase inhibitor
(PTK787/ZK222584) in Myelodysplastic Syndrome.
CTSU E-2603 A Double-blind, randomized, placebo-controlled Phase III trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and placebo in patients with Unresectable Locally Advanced or Stage IV Melanoma.
CTSU E-2204 An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely Resected Pancreatic Carcinoma.
C 90202 A randomized, double-blind placebo-controlled phase III study of early vs. standard Zoledronic Acid to prevent skeletal related events in men with prostate cancer metastatic to bone.
C 90401 A randomized double-blinded placebo controlled phase III trial comparing Docetaxel and Prednisone with and without Bevacizumab in men with hormone refractory prostate cancer.
CTSU E-3805 CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer.
CTSU R-0521 A Phase III protocol of androgen suppression (AS and 3DCRT/IMRT vs. AS and 3D CRT/IMRT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer. (Only 3D CRT will be offered).
CTSU E-2805 A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitnib vs. Sorafenib vs. Placebo in Patients with Resected Renal Cell Carcinoma
CTSU S-0505 Phase II Trial of BAY 43-9006 in Advanced Soft Tissue Sarcomas. (TEMPORARILY SUSPENSION 2/1/07)
S
0000A Prevention
of Alzheimer's Disease With Vitamin E and Selenium Trial
S
0000B Prevention
of cataract and age-related macular degeneration with Vitamin E and Selenium
- (SEE), phase III ancillary to S-0000 SELECT
I-ELCAP
|
|
C.R. Wood
Cancer Center Research |
Glens Falls Hospital |
